BioLineRx has received two notices of allowance from USPTO for BL-1021, an orally available small molecule for treating neuropathic pain.
The first notice of allowance is issued for patent application claiming BL-1021's composition. Once issued, the patent will be valid until at least September 2022.
The second one is issued for application claiming the use of BL-1021 for the treatment of pain, which will be valid until at least January 2028 when issued.
BioLineRx CEO Kinneret Savitsky said BL-1021 may present an improved treatment for such patients, greatly improving their quality of life.
Additional patents claiming BL-1021's composition are granted or pending in Australia, Canada, China, Europe, Israel, Japan, Korea, Mexico and India.
Additional patents claiming the use of BL-1021 as pain therapy are pending in Australia, Canada, China, Europe, Israel, Japan, Korea, Mexico and India.
